Sarcoma Clinical Trials

Showing 1-15 of 15 items
1.
2.
3.
4.
  • Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
  • Background: - Alveolar soft part sarcoma is a rare type of tumor that has a lot of blood vessel growth. Cediranib and sunitinib are two cancer treatment drugs that work by blocking the growth of new blood vessels. This may help to stop tumor growth. Some patients with alveolar soft part sarcoma treated with cediranib or sunitinib had tumors that either decreased in size or remained stable without growth for a long time. More research is needed to see whether these drugs can be approved as a standard treatment for alveolar soft part sarcoma. Objectives: - To test the safety and effectiveness of cediranib and sunitinib to treat alveolar soft part sarcoma. - To determine the objective response rate of cediranib and sunitinib in patients with alveolar soft part sarcoma. Eligibility: - Individuals at least 16 years of age who have alveolar soft part sarcoma. - Individuals who have not received prior cediranib or sunitinib. Design: - All participants will be screened with a physical exam and medical history. They will also have blood and urine tests, tumor imaging studies, and biopsies. - Participants will be divided into two groups: one group will start with cediranib and the other will start with sunitinib. - During Part I of the study, participants will take cediranib or sunitinib by mouth once a day. They will continue this routine every day for 28 days (one cycle of treatment). They will stop taking the drug if the side effects become too severe or the tumor starts growing again. - Participants will not have any cancer treatment for 2 weeks before starting Part II. - During Part II, participants will receive the other study drug (cediranib or sunitinib). However, if one of the drugs is not effective or its side effects are too severe, participants will not receive the drug and will stop being in the study. - Participants will be monitored with frequent blood and urine tests. They will also have tumor imaging studies and other tests.
  • Diagnoses: Pediatric Sarcoma, Sarcoma
  • Status: Recruiting
5.
6.
7.
  • Lenalidomide in Treating Patients With AIDS-Related Kaposi Sarcoma
  • RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide and to see how well it works in treating patients with AIDS-related Kaposi sarcoma.
  • Diagnoses: Sarcoma
  • Status: Recruiting
8.
  • Nilotinib With Radiation for High Risk Chordoma
  • The study drug, Nilotinib, is believed to slow down tumor growth by regulating a gene involved in cellular growth of chordoma cells. During this research study, subjects will also receive radiation therapy which is considered a standard treatment for advanced chordomas. It is hoped by adding nilotinib, the benefits of radiation therapy can be enhanced without adding significant toxicities. The purpose of this research study is to determine the safety of nilotinib when used in combination with radiation therapy, and the highest dose of nilotinib that can be given safely with radiation therapy.
  • Diagnoses: Sarcoma
  • Status: Recruiting
9.
10.
  • Bevacizumab/Doxorubicin/Radiation for Sarcoma
  • The main purpose of this study is to test the safety, tolerability, maximum tolerated dose, and effectiveness of bevacizumab in combination with chemotherapy and radiation therapy. Because bevacizumab is not considered standard therapy for sarcomas, it can only be given to subjects with sarcoma who are enrolled in this research study and may only be administered under the direction of doctors who are investigators in this research study. This study is being done because sarcomas can recur after surgical resection (surgery for removal of the tumor), radiation therapy and chemotherapy. This recurrence can occur in the same location as the original tumor or in distant sites such as the lung. Thus better treatments are needed. This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug, combination of drugs, or combination of drugs with radiation. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the combination of drugs and radiation is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved bevacizumab with doxorubicin and radiation for your type of cancer.
  • Diagnoses: Sarcoma
  • Status: Recruiting
11.
12.
13.
14.
  • Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650 AM1)
  • This study is being done to evaluate the safety and pharmacokinetic profile of MK-8242 in participants with advanced solid tumors. In Part 1 of the study, the study drug dose will be escalated to determine the maximum tolerated dose (MTD). In Part 2 of the study, the MTD will be confirmed and the recommended Phase 2 dose (RPTD) established; the effect of MK-8242 on liposarcoma and other tumor types will also be evaluated.
  • Diagnoses: Sarcoma
  • Status: Recruiting
15.
  • Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma
  • RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether surgery is more effective with or without radiation therapy in treating nonmetastatic retroperitoneal soft tissue sarcoma. PURPOSE: This randomized phase III trial is studying radiation therapy followed by surgery to see how well it works compared with surgery alone in treating patients with previously untreated nonmetastatic retroperitoneal soft tissue sarcoma.
  • Diagnoses: Sarcoma
  • Status: Recruiting
Showing 1-15 of 15 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms